SOX11 overexpression is a specific marker for mantle cell lymphoma and correlates with t(11;14) translocation, CCND1 expression and an adverse prognosis According to the WHO classification, B-cell lymphomas can be divided in several subgroups depending on their morphological and phenotypic properties. 1 Mantle cell lymphoma (MCL) accounts for 5-10% of mature B-cell neoplasms and are believed to derive from naive B cells. MCL are usually positive for CD5, CD20 and CD43, but are negative for CD10 and BCL6. CD23 is negative or weakly expressed. 1 Diagnosis of MCL is based on cytomorphology, histology, immunophenotype as well as presence of a t(11;14)(q13;q32)/IGH-CCND1 rearrangement or demonstration of cyclin D1 (CCND1) overexpression. 2 However, some cases that are considered by expression profiling or immunophenotyping to belong to the MCL entity lack the t(11;14) translocation and the CCND1 overexpression and thus are difficult to distinguish from other mature B-cell neoplasms. 3, 4 This distinction is clinically very relevant as true MCLs show an aggressive behavior, whereas many other B-cell lymphomas do not. MCL usually shows a rapid clinical evolution, poor response to conventional therapeutic regimes, frequent relapses and a median survival of 3-4 years. 5 Fortunately, new therapies seem to significantly improve the progression-free survival. 6 SOX11 is a neural transcription factor involved in tissue remodeling in embryogenesis. 7, 8 The overexpression of SOX11 has been demonstrated to be specific for MCL independent of CCND1 positivity, suggesting a diagnostic role of SOX11 expression in t(11;14)-negative MCLs.
4,9,10 SOX11 is not expressed in other lymphoid neoplasms, with the exception of lymphoblastic lymphoma, some Burkitt lymphomas and T-prolymphocytic leukemia, which are readily discriminated from MCL by standard diagnostics. 4 The prognostic role of SOX11 expression has been controversially discussed. [10] [11] [12] [13] Recently, some studies have identified a group of MCL patients with an indolent clinical course and a long survival.
14 Subsequently, the absence of SOX11 expression was described as diagnostic marker of these indolent MCLs. 11 In this study, we evaluated the applicability and usefulness of SOX11 expression as a diagnostic marker for differentiation of mature B-cell neoplasms and to determine its impact on outcome.
We analyzed 219 patients with mature B-cell neoplasms that were diagnosed by cytomorphology, immunophenotyping, cytogenetics and fluorescence in situ hybridization, and based on these methods categorized into t(11;14)-positive MCL (n ¼ 100), and SOX11-A: 5 0 -CCCTCCACCCTACCACCG-3 0 . Detection probes were as follows: SOX11-FL: 5 0 -TCACCACTACAACTTCCTCCCAAGGA ACCC-FL and SOX11-LC640: LC640-GCTCTGCACCCTCCGAGAGAAA GAGCGA-Pho. CCND1 was analyzed as described before. 15 The gene expression levels were quantified using reference plasmid DNA containing SOX11 or ABL1 sequences, and are given relative to the expression of the housekeeping gene ABL1. Based on a negative control cohort (n ¼ 40) comprising 21 peripheral blood (PB) and 19 bone marrow (BM) samples without evidence for
expression ratio malignancy the cutoff for rating the expression ratio positive was calculated by the mean value plus the threefold s.d. and resulted in 0.28 in PB and 0.29 in BM for SOX11.
In the total cohort, elevated SOX11 expression was present in 95/219 cases (43%) and was strongly associated with a t (11;14) translocation (84/100, 84% in t(11;14)-positive cases versus 11/119, 9% in t(11;14)-negative cases, Po0.001). Correspondingly, SOX11 expression was more frequent in CCND1-expressing cases in comparison to CCND1-negative cases (85/108 (79%) in CCND1-positive cases versus 10/111 (9%) in CCND1-negative cases, Po0.001) ( Table 1) . Also the absolute expression levels of both genes showed a high correlation (Spearman correlation coefficient: 0.587, Po0.001; Figure 1a) . SOX11-positive patients were younger (66.1 versus 70.0 years; P ¼ 0.007), showed a slightly lower hemoglobin level (12.0 versus 13.5 g/dl; P ¼ 0.007) and a lower platelet count (145 000 versus 184 000/ml; Po0.001). Details are given in Table 1 . A detailed analysis within the respective diagnostic subgroups revealed that SOX11 was expressed in 84/100 (84%) t(11;14)-positive MCL cases with an overall highexpression level (median: 49.9; range: 0.3-1063.8). As expected in this entity, all cases were CCND1-positive. The resulting amount of 16% CCND1 þ /SOX11 À cases is slightly higher but in line with the reported 7-13%. 4, [9] [10] [11] In the group of 49 t(11;14)-negative mature B-cell neoplasms with an MCL-typical immunophenotype, 9 cases (total 9/49, 18%) showed a SOX11 expression (median: 1.7; range: 0.4-322.7), suggesting that these 9 cases might be considered t(11;14)-negative MCLs. In three of these nine cases, histology information was available and confirmed a MCL-typical histology, why we included these three cases as t(11;14)-negative MCLs. Two of the 40 CLL/PL cases were SOX11-positive but lacked t (11;14) and CCND1 expression; however, these patients are clearly diagnosed as CLL/PL by immunophenotyping and did not show a MCL-typical immunophenotype. In contrast, SOX11 was never rated positive in classical CLL cases, whereas one case showed high CCND1 expression, although t(11;14) negative (see Table 1 ). The mutational status of IGHV was analyzed in a subgroup of patients (n ¼ 112), including MCL (n ¼ 60), CLL/PL (n ¼ 29) and CLL (n ¼ 23) patients, and was compared to public databases (IMGT/V-QUEST; http://www.imgt.org). There was no significant correlation of the IGHV mutational status with SOX11 expression (26 unmutated and 35 mutated IGHV within SOX11-negative cases versus 30 unmutated and 25 mutated cases in SOX11-expressing patients) ( Table 1) . This was more prominently reflected in MCL, where SOX11-negative patients showed more often a hypermutated IGHV than SOX11-expressing patients (10/15, 67% in SOX11 À versus 30/74, 41% in SOX11 þ ; P ¼ 0.088). CD23 is an IgE Fc receptor and a marker for activated B cells, but not or weakly expressed on resting mature B cells. Among mature B-cell neoplasms, its expression is useful for distinguishing CLL and MCL cases. However, a small subset of MCL cases show CD23 expression. 12 We correlated the CD23 expression (% positive cells) with SOX11 expression, but no correlation was detectable (59% CD23 þ cells in SOX11 À patients versus 60% in SOX11 þ patients). For a total of 107 patients the time-totreatment (TTT) was available. In the total cohort, cases with SOX11 expression had a shorter TTT as compared with those without (median TTT: 37 versus 56 months, P ¼ 0.011), this was also true for CCND1-positive (median TTT: 37 versus 58 months, P ¼ 0.07) and t(11;14)-positive cases (median TTT: 6 versus 56 months, P ¼ 0.003), probably reflecting the indication for therapy by diagnosis of MCL due to its aggressive behavior (Figure 1b) . Small case numbers of SOX11 À and SOX11 þ patients within the four analyzed diagnostic subgroups allowed no valid analysis within the individual groups. However, separate analysis of MCLs (t(11;14)-positive and -negative) revealed that SOX11-positive patients showed a more indolent course compared with SOX11-negative MCLs (37 versus 4.5 months, P ¼ n.s.) (Figure 1b) . Further, SOX11 þ /t(11;14) À cases showed a more adverse prognosis than SOX11 þ /t(11;14) þ MCL patients; however, follow-up data was only available for three of these nine t(11;14) À /SOX11 þ patients (median TTT SOX11 þ /t(11;14) À : 1.3 versus 37 months in SOX11 þ /t(11;14) þ cases; P ¼ n.s.). In agreement with our findings, Wang et al. 10 and Nygren et al. 12 showed a shorter overall survival (OS) of 16 and 18 months of SOX11-negative MCL patients in contrast to 49 and 38 months in SOX11-expressing MCL patients. In contrast, Fernandez et al. 11 analyzed 112 MCL cases and reported a better 5-year OS of SOX11-negative MCL patients of 78% in contrast to SOX11-positive patients (36%) and therefore, defined beside other markers, the absence of SOX11 as a marker for the indolent MCL subtype. This furthermore illustrates the controversial discussion regarding the prognostic impact of SOX11 expression in MCL, which may be due to low case numbers of SOX11 À cases in all studies. Summarized, some rare mature B-cell neoplasms are considered to belong to the MCL entity but lack the t(11;14) and CCND1 overexpression. The differential diagnosis of this entity from other mature B-cell neoplasms is difficult. SOX11 expression may be considered as a useful marker in addition to CCND1 expression in t(11;14)-negative MCL, as the only missing hallmark of these MCL cases is a t (11;14) . Overall, patients with SOX11 expression showed a shorter TTT and SOX11-expressing MCL patients showed probably a more indolent course, but further analyses within a larger cohort are warranted to prove the independent diagnostic role of SOX11 expression as well as its prognostic impact. Multiple myeloma is the most common form of neoplasm affecting or involving the bone, accounts for 1% of all cancer types with a lifetime risk of 0.62%, and new cases are now estimated at 21 700 adults in the United States per year. 1 This plasma cell dyscrasia is characterized by clonal proliferation of neoplastic plasma cells producing osteoclast-activating and osteoblast-inhibiting factors. 2, 3 Clinical symptoms result from pathological fractures at the site of osteolytic lesions or profound osteoporosis, often resulting in hypercalcemia. 3 Symptomatic fractures are most commonly seen in the vertebral bodies centered in the thoracolumbar region. 1, 4, 5 These types of compression fractures result in significant pain, decreased activity levels, disability and increased morbidity. [6] [7] [8] We describe the fracture distribution and the efficacy of vertebral augmentation (vertebroplasty or kyphoplasty) in 792 consecutive patients with myeloma-related symptomatic compression fractures, who underwent 2693 vertebral augmentations at the University of Arkansas for Medical Sciences between January 2001 to May 2007. Information was collected on type of augmentation (vertebroplasty or kyphoplasty), patient vitals, magnetic resonance imaging, computed tomography (CT) and Positron emission tomography-CT for vertebral fracture location. All of the patients were on cancer therapy or about to receive therapy. Pre-and postprocedure pain, medication and activity level were assessed by survey in a subset of 361 subjects. When the participants were not in hospital to complete the survey, surveys were mailed to patient-reported addresses, which were often not reflective of their current living situation, as most patients (80%) had relocated to the local area for treatment. Efficacy was assessed by changes in pain with the Visual Acuity Scale (VAS), analgesic usage and activity level pre-procedure and 1 month post procedure by chart documentation and patient survey. All patients received 1 g Cefazolin (Ancef) pre-procedure. Institutional Review Board approval was obtained for this study.
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STATISTICAL METHODS
As many of the subjects participating in the outcomes study underwent multiple sessions, clustering of sessions within subjects was addressed by using mixed models with a random effect for subject for analyzing change in pain score, and generalized mixed models with a fixed effect for time and a random effect for subject for pain medication and physical activity.
For modeling, pain medication was dichotomized as narcotics versus all other categories and activity as no limitation or walking without assistance versus all other categories. Additional models explored age, gender, session number (first or subsequent), number of augmentations and type of repair. Outcomes were also analyzed by repair region (I-vertebra (T)T1-T10, II-thoracic (T)11-lumbar (L)2 or III-L3-sacrum) for the subset having repair(s) to a single region (excluding those with repairs X1 region). To assess response bias, demographics and procedure distributions were compared between those participating in the outcomes study and those with only procedural data.
RESULTS
Of the 792 patients who underwent vertebroplasty or kyphoplasty, the median age was 63 years (range, 16-99) with 76 (10%) patients being 80 years and older, and 56% of patients were males. These patients underwent a total of 1072 sessions; the majority of patients (75%) had one vertebral augmentation session, 18% of patients had two vertebral augmentation sessions, 7% had three to six sessions. The number of repairs varied per session with the median being 2 (interquartile range (IQR) 1-3) repairs per session with 23% of sessions involving four to nine augmentations. The majority (83%) of the 2693 levels treated were repaired with vertebroplasty. The distribution of vertebroplasty repairs was 37% for T1-T10, 39% for T11-L2 and 24% for L3-sacrum (Figure 1a) . Overall, 68% of all sessions involved repair on X2 vertebra, and a similar distribution across levels was seen for patients with kyphoplasty. Two complications (0.3%) required antibiotics. No neurological deficits were observed.
Pre-and post-assessments For the outcomes study, 361 participants provided both pre-and post-assessments (1 month) for 447 sessions for at least one of the three outcomes (VAS, analgesic medications, or activity level assessments). Of these participants, 82% had assessments for one session only, 15% for two sessions and 4% for three or four sessions. Patients participating in the outcomes study were significantly more likely to be younger (median, 60 vs 65), male (63 vs 50%) and from out of state (66 vs 36%) than those who were non-participants (Table 1) . Most patients were from out of state and relocated to the area for treatment. The number of levels repaired did not differ significantly with the median being 2 (IQR, 1-3) for both participants and non-participants.
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